(P048) Quality Assurance Assessment of Diagnostic and Therapy Simulation Computed Tomography Image Registration for Head and Neck Radiotherapy: Anatomic Region of Interest–Based Comparison of Rigid and Deformable Algorithms

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

The purpose of this study was to develop a workflow process that enables quantitative assessment of different image registration techniques used for head and neck simulation CT to diagnostic CT coregistration.

Abdallah S. Mohamed, MD, MSc, Manee-Naad Ruangskul, MD, Musaddiq J. Awan, MD, Charles A. Baron, MD, Richard Castillo, PhD, Edward Castillo, PhD, Thomas M. Guerrero, MD, PhD, Esengul Kocak-Uzel, MD, Jinzhong Yang, PhD, Laurence Court, PhD, G. Brandon Gunn, MD, Adam S. Garden, MD, David I. Rosenthal, MD, Clifton D. Fuller, MD, PhD; UT MD Anderson Cancer Center

Background and Purpose: Developing a framework to validate the performance of image registration algorithms is critical before application for tumor localization and therapeutic targeting. The purpose of this study was to develop a workflow process that enables quantitative assessment of different image registration techniques used for head and neck simulation CT (SimCT) to diagnostic CT (DxCT) coregistration.

Materials and Methods: A total of 68 reference anatomic regions of interest (ROIs) were manually contoured on each of 11 paired SimCTs and DxCTs of head and neck patients treated with definitive intensity-modulated radiotherapy (IMRT). DxCT was registered to SimCT rigidly and through four different deformable image registration (DIR) algorithms: Atlas-based, b-spline, demons, and optical flow. The resultant deformed ROIs were compared with manually contoured reference ROIs using similarity coefficient metrics (ie, Dice similarity coefficient) and surface distance metrics (ie, 95% maximum Hausdorff distance).

Results: All DIR algorithms showed improved performance over rigid registration for all used comparison metrics (Steel test: P < .008 after Bonferroni correction), excepting optical flow for surface distance metrics. The Atlas-based algorithm had the best DIR performance (mean Dice of 0.65 ± 0.15, mean false-negative Dice of 0.11 ± 0.18, mean false-positive Dice of 0.58 ± 0.26, and mean 95% maximum Hausdorff distance of 6.79 mm ± 7.6). The performance of different algorithms varied substantially for specific anatomic ROIs and subgroups. Overall, the performance of most algorithms was better in matching bony and cartilaginous ROIs than muscular, glandular, vascular, and other soft tissue ROIs.

Conclusions: Development of a formal ROI-based quality assurance workflow for registration assessment revealed improved performance with DIR techniques over rigid fusion and provided head and neck ROI-specific benchmarks for DxCT-SimCT coregistration for future efforts. After QA, DIR implementation should be the standard for head and neck DxCT-SimCT allineation.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content